Tag - FULC

Fulcrum Therapeutics

SVB Leerink starts Fulcrum Therapeutics at OP; PT $20

SVB Leerink initiated coverage of Fulcrum Therapeutics (NASDAQ:FULC) with an “outperform” rating and price target of $20 in 12 months. The stock closed at $11.62 on Aug. 9. Fulcrum is a clinical-stage biopharmaceutical...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.